You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 20, November 26, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Letters
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Pulmonary Diseases, Other
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Viral Infections
 •Alert me on articles by topic

Temporal Patterns of Hepatic Dysfunction and Disease Severity in Patients With SARS

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Mildly elevated levels of aminotransferase have been reported in 23% to 50% of patients with severe acute respiratory syndrome (SARS). The clinical and pathological significance of this finding, however, remains unknown.1-3 We investigated whether liver dysfunction might reflect disease activity and have a temporal relationship with other clinical parameters in patients with SARS.

Methods

We evaluated clinical records, serial blood test results, and chest radiographs of 54 adult patients with SARS (diagnosed according to US Centers for Disease Control and Prevention criteria1, 4) but without chronic hepatitis B or C infection, who were admitted to 2 Hong Kong regional hospitals between March 8 and April 17, 2003. Charts of randomly selected age- and sex-matched patients with non-SARS community-acquired pneumonia from Queen Mary Hospital in the same time period were also examined. All patients with SARS received combination therapy comprising a corticosteroid and either intravenous or oral ribavirin, beginning . . . [Full Text of this Article]

Wai-Man Wong, MD; James C. Ho, MD; Ivan F. Hung, MD; William Ng, MD; Yui-Ming Lam, MD; Wai-On Tam, MD; Benjamin C. Y. Wong, MD; Poon C. Wong, MD; Ching Lung Lai, MD; Wah-Kit Lam, MD; Shiu-Kum Lam, MD; Kenneth W. Tsang, MD
Department of Medicine

Gaik C. Ooi, MD
Department of Diagnostic Radiology

Pak L. Ho, MD
Department of Clinical Microbiology

Thomas Mok, MD; Johnny Chan, MD
Department of Medicine
Queen Elizabeth Hospital
Hong Kong, China



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances
Nichols et al.
Clin. Microbiol. Rev. 2008;21:274-290.
ABSTRACT | FULL TEXT  

Diagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt?
Tsang et al.
Eur Respir J 2004;24:1025-1032.
ABSTRACT | FULL TEXT  

Severe acute respiratory syndrome (SARS): epidemiology and clinical features
Hui et al.
Postgrad. Med. J. 2004;80:373-381.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.